Table 2.
The reasons for treatment discontinuation in the first-line and second-line therapy.
| Factor | First-line therapy (n = 307) (%) | Second-line therapy (n = 131) (%) |
|---|---|---|
| Progressive disease | 165 (54.0) | 68 (51.8) |
| Adverse events | 113 (36.7) | 42 (32.1) |
| Fatigue | 32 (10.4) | 10 (7.6) |
| Appetite loss | 22 (7.2) | 10 (7.6) |
| Proteinuria | 15 (4.9) | 4 (3.1) |
| Liver disorder | 13 (4.2) | 6 (4.6) |
| Diarrhea | 9 (2.9) | 3 (2.3) |
| HFSR | 8 (2.6) | 5 (3.8) |
| Thrombocytopenia | 5 (1.6) | 1 (0.8) |
| Fever | 4 (1.3) | 2 (1.5) |
| Pneumonia | 3 (0.9) | 1 (0.8) |
| Skin disorders | 2 (0.7) | 0 (0.0) |
| Hepatic decompensation | 16 (5.1) | 12 (9.2) |
| Ascites | 7 (2.3) | 9 (6.9) |
| Encephalopathy | 5 (1.6) | 3 (2.3) |
| Hemorrhage | 3 (0.9) | 0 (0.0) |
| Jaundice | 1 (0.3) | |
| Conversion | 1 (0.3) | 1 (0.8) |
| Others | 12 (3.9) | 8 (6.1) |
HFSR hand-foot-syndrome-reaction.